Cullinan Therapeutics has received FDA Orphan Drug Designation for CLN‑049 in relapsed/refractory AML, a bispecific FLT3xCD3 T‑cell engager under Phase 1 evaluation. The designation underscores urgent need in AML, where survival rates remain below 10%, and builds on prior Fast Track status.
Written By: Mahathi Palivela, PharmD
Reviewed By: Pharmacally Editorial Team
Cullinan Therapeutics has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CLN‑049 in relapsed/refractory acute myeloid leukemia (AML), strengthening regulatory support for the company’s emerging immunotherapy program in difficult‑to‑treat blood cancers.
The designation provides incentives including tax credits, user fee waivers, and seven years of market exclusivity upon approval, underscoring the potential impact of CLN‑049 in a high‑need setting.
CLN‑049 is a bispecific FLT3xCD3 T‑cell engager currently under Phase 1 evaluation in patients with relapsed/refractory AML and myelodysplastic syndrome (MDS). By simultaneously binding FLT3 and CD3, CLN‑049 redirects T cells toward FLT3‑expressing leukemia cells.
Unlike several FLT3‑targeted approaches restricted to mutated disease, CLN‑049 targets both mutated and wild‑type FLT3, potentially expanding treatment applicability across a broader AML population.
The program addresses a major unmet need in AML, where outcomes after relapse remain dismal. Five‑year survival rates in relapsed/refractory AML are near or below 10%, particularly among patients with high‑risk genomic features such as TP53 mutations or complex cytogenetics. Despite advances in targeted therapies, no immunotherapy has yet gained approval for AML, highlighting the novelty of CLN‑049’s approach.
Cullinan is evaluating intravenously administered CLN‑049 in an ongoing first‑in‑human Phase 1 dose‑escalation study (NCT05143996) assessing safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti‑leukemic activity in relapsed/refractory AML and MDS patients.
A parallel European Phase 1 study is investigating the therapy in AML patients with measurable residual disease. Together, these studies are designed to establish the foundation for dose expansion and future registrational strategies.
Chief Medical Officer Jeffrey Jones noted that the orphan designation highlights both the urgent need for new therapies in relapsed/refractory AML and the potential role of FLT3‑directed T‑cell engagement in patients with limited treatment options, including those with TP53‑mutated disease.
CLN‑049 had previously received FDA Fast Track designation for relapsed/refractory AML, and ongoing Phase 1 data are expected to guide next‑stage development in high‑risk AML populations.
Reference
About the Writer
Mahathi Palivela (LinkedIn) is pursuing PharmD and has a strong interest in Clinical Pharmacy and Patient safety. She is passionate about handling and analyzing patient data, and translating clinical insights into clear, meaningful summaries. She aims to apply this interest in Medical Writing and Pharmacovigilance, focusing on improving patient outcomes through careful data interpretation and communication.